Over the weekend, President Donald Trump announced tariffs on the U.S.'s top three trading partners—Canada, Mexico, and China—and threatened similar measures against the EU. On Monday, U.S. stocks experienced a selloff, with the major indices dropping. Losses narrowed, however, after news broke of a delay in imposing tariffs on Mexico. Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
tsla trader
:
tariffs ? according to Peterson institute/ piie , effect on GDP and inflation is limited, although twisted trading policy is bad for world trade the least affected industry could be a buy
$Esperion Therapeutics (ESPR.US)$Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share. Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
$Esperion Therapeutics (ESPR.US)$Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry: 1. Unique Market Position in Statin Alternatives – Addressing Statin Intolerance: There are millions of statin...
$Esperion Therapeutics (ESPR.US)$$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
6
9
1
Report
Millaai
:
You're under duvet, are you looking for a successor everywhere
Growth Investor27
Millaai
:
The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
Detached House
Millaai
:
You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
This unique biotech$Esperion Therapeutics (ESPR.US)$Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
14
1
4
Report
10xStockPicks
OP
:
This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.
It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare underperformed. So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look. 1. Boeing (down 36.5%) Boeing$Boeing (BA.US)$has had a r...
3
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Amgen Stock Forum
AMGN, MRNA, PFE, JNJ ARE SAME BUS OR NOT = AMGN, MRNA, PFE, JNJ SEM BUT ZAY KO 🤔
Market worries over the tariffs focus on two key issues. U.S. companies that depend heavily ...
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...
So what are the five worst performers on the Dow Jones Industrial Average list of blue chip stocks? Let's take a look.
1. Boeing (down 36.5%)
Boeing $Boeing (BA.US)$ has had a r...
No comment yet